EMBC: Embecta Company Sales Revenue

Can Embecta Corp. (EMBC) maintain its leadership in the insulin delivery systems niche due to high barriers to entry? The company's product sales confirm this status, where the indicator value is 1.02. However, logistical disruptions and sanctions create raw material supply risks. Meanwhile, stable demand for consumables provides the enterprise with a steady cash flow and operational resilience.

Revenue and Sales Volume: Embecta (EMBC) for 04/28/2023 - 11/13/2026

Comprehensive metric breakdowns and analytics for Embecta (EMBC)

- current price and projected stock value:

Share Price Embecta Health|EMBC - Consensus Target

- market capitalization information:

Market Value Embecta Corp.|EMBC - Total Company Value

- balance sheet net asset value indicators:

Accounting Value per Share Embecta|EMBC - Book Capitalization|Market-to-Book Ratio embecta.com|EMBC - Company Total Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

EMBC - Net Income|Expected Net Income Embecta Corp.|EMBC - P/E Multiple|Projected Price to Earnings Ratio embecta.com|EMBC - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple Embecta Corp.|EMBC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Embecta|EMBC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months embecta.com|EMBC - Earnings per share growth in current year|Net earnings per share change forecast for next year Embecta Corp.

- company sales and revenue statistics:

EMBC - Company Revenue|Company Future Sales Volume Embecta Health|EMBC - P/S Multiple|Market Cap to Future Revenue Ratio Embecta Corp.

Summary company analysis:EMBC Embecta Health

Cash flow stability determines the operational resilience and credit profile of the issuer. This indicator captures the daily volume of products sold, reflecting the effectiveness of pricing policy and market demand. For Embecta Corp. (EMBC), which focused on diabetology following its spin-off from BD, this confirms the success of its narrow specialization. Management's expense discipline directly impacts the conversion of revenue into profit. The trend in the company's commercial revenue clearly demonstrates the scalability of the chosen business model.

Key competitors